Sequential Combo Immuno and Target Therapy (SECOMBIT) Study
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the best sequencing approach with the combination of target agents (LGX818 plus
MEK162) and the combination of immunomodulatory antibodies (ipilimumab plus nivolumab) in
patients with metastatic melanoma and BRAF V600 mutation.